The Conversation (0)
Liberty Leaf Holdings announced the completion of its first CBD research study for pain medication on dogs.
Liberty Leaf Holdings (CSE:LIB) announced the completion of its first cannabidiol (CBD) research study for pain medication on dogs.
As quoted in the press release:
Study Results
Results from the ESEV-managed, randomized, placebo-controlled clinical trial demonstrated that dogs with clinically diagnosed OA receiving a daily dose of only 0.3 mg/kg of proprietary CBD-infused oil formulation for four weeks exhibited significantly reduced pain and improved functional performance. Daily CBD dosages for dogs have generally and arbitrarily been recommended in the range of 2-20 mg/kg.
“The ability to effectively manage pain with such a low CBD dosage as used in this study and over such a short treatment period is statistically significant,” said Robert Jackman, Scientific Project Manager for Liberty Leaf.
According to Jackman, of the 16 dogs included in the study, only one did not benefit from the CBD treatment. The proprietary CBD-infused oil formulation used in the study was well tolerated, with no adverse or side effects reported by dog owners.
“This project was operated in multiple locations by a few different groups of researchers and project managers,” noted Golan Vaknin, Executive Director for ESEV. He commented further. “The study was conducted productively and efficiently, and we are happy with the promising results showing positive effects of CBD for chronic pain in dogs.”
